Adaptic® Tsjekkia - tsjekkisk - Adama

adaptic®

adama - rozpustný koncentrát - amonium sulfate + polyacrilamid - smáčedla

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotické činidla - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

RIVAROXABAN SANDOZ 10MG Potahovaná tableta Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

rivaroxaban sandoz 10mg potahovaná tableta

sandoz s.r.o., praha array - 17116 rivaroxaban - potahovaná tableta - 10mg - rivaroxaban

RIVAROXABAN SANDOZ 15MG+20MG Potahovaná tableta Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

rivaroxaban sandoz 15mg+20mg potahovaná tableta

sandoz s.r.o., praha array - 17116 rivaroxaban; 17116 rivaroxaban - potahovaná tableta - 15mg+20mg - rivaroxaban

Deltyba Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

deltyba

otsuka novel products gmbh - delamanid - tuberkulóza, multirezistentní - antimykobakteriální látky - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 a 5. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.

Viracept Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

viracept

roche registration ltd. - nelfinavir - hiv infekce - antivirotika pro systémové použití - viracept je uvedeno v antiretrovirové léčbě lidské imunodeficience (hiv-1)-infikovaných dospělých, mladistvých a dětí starších tří let. v proteázové inhibitory (pi)-zkušenosti pacientů, volba nelfinaviru by měla být založena na individuálním testování virové rezistence a na posouzení předchozí léčby.

ORLISTAT TEVA 60MG Tvrdá tobolka Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

orlistat teva 60mg tvrdá tobolka

teva pharmaceuticals cr, s.r.o., praha array - 10917 orlistat - tvrdá tobolka - 60mg - orlistat

Dapagliflozin Viatris Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - léky užívané při diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Malaseb Šampon Tsjekkia - tsjekkisk - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

malaseb šampon

dechra veterinary products a-s - mikonazol, kombinace - Šampon - imidazol a triazolové deriváty - psi, kočky

MEGACAL–M BVP Injekční roztok Tsjekkia - tsjekkisk - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

megacal–m bvp injekční roztok

b.v.p. (ballinskelligs veterinary products) - vápník, kombinace s vitaminem d a / nebo jinými léky - injekční roztok - vÁpnÍk - skot